Melanoma Immunotherapy: Next-Generation Biomarkers

被引：45

作者：

Hogan, Sabrina A. ^{[1
,2
]}

Levesque, Mitchell P. ^{[1
,2
]}

Cheng, Phil F. ^{[1
,2
]}

机构：

[1] Univ Spital Zurich, Dept Dermatol, Zurich, Switzerland

[2] Univ Zurich, Fac Med, Zurich, Switzerland

来源：

FRONTIERS IN ONCOLOGY | 2018年 / 8卷

关键词：

melanoma; immunotherapy; biomarkers; next-generation sequencing; review literature as topic; IPILIMUMAB PLUS DACARBAZINE; METASTATIC MELANOMA; PD-1; BLOCKADE; LACTATE-DEHYDROGENASE; ANTI-PD-1; THERAPY; CLINICAL-RESPONSE; PERIPHERAL-BLOOD; CTLA-4; MASS CYTOMETRY; CANCER;

D O I：

10.3389/fonc.2018.00178

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The recent emergence of cancer immunotherapies initiated a significant shift in the clinical management of metastatic melanoma. Prior to 2011, melanoma patients only had palliative treatment solutions which offered little to no survival benefit. In 2018, with immunotherapy, melanoma patients can now contemplate durable or even complete remission. Treatment with novel immune checkpoint inhibitors, anti-cytotoxic T-lymphocyte protein 4 and anti-programmed cell death protein 1, clearly result in superior median and long-term survivals compared to standard chemotherapy; however, more than half of the patients do not respond to immune checkpoint blockade. Currently, clinicians do not have any effective way to stratify melanoma patients for immunotherapies. Research is now focusing on identifying biomarkers which could predict a patient's response prior treatment initiation (or very early during treatment course), in order to maximize therapeutic efficacy, avoid unnecessary costs, and undesirable heavy side effects for the patient. Given the rapid developments in this field and the translational potential for some of the biomarkers, we will summarize the current state of biomarker research for immunotherapy in melanoma, with an emphasis on omics technologies such as next-generation sequencing and mass cytometry (CyTOF).

引用

页数：10

共 61 条

[1] Genomic Classification of Cutaneous Melanoma [J].

Akbani, Rehan ;

Akdemir, Kadir C. ;

Aksoy, B. Arman ;

Albert, Monique ;

Ally, Adrian ;

Amin, Samirkumar B. ;

Arachchi, Harindra ;

Arora, Arshi ;

Auman, J. Todd ;

Ayala, Brenda ;

Baboud, Julien ;

Balasundaram, Miruna ;

Balu, Saianand ;

Barnabas, Nandita ;

Bartlett, John ;

Bartlett, Pam ;

Bastian, Boris C. ;

Baylin, Stephen B. ;

Behera, Madhusmita ;

Belyaev, Dmitry ;

Benz, Christopher ;

Bernard, Brady ;

Beroukhim, Rameen ;

Bir, Natalie ;

Black, Aaron D. ;

Bodenheimer, Tom ;

Boice, Lori ;

Boland, Genevieve M. ;

Bono, Riccardo ;

Bootwalla, Moiz S. ;

Bosenberg, Marcus ;

Bowen, Jay ;

Bowlby, Reanne ;

Bristow, Christopher A. ;

Brockway-Lunardi, Laura ;

Brooks, Denise ;

Brzezinski, Jakub ;

Bshara, Wiam ;

Buda, Elizabeth ;

Burns, William R. ;

Butterfield, Yaron S. N. ;

Button, Michael ;

Calderone, Tiffany ;

Cappellini, Giancarlo Antonini ;

Carter, Candace ;

Carter, Scott L. ;

Cherney, Lynn ;

Cherniack, Andrew D. ;

Chevalier, Aaron ;

Chin, Lynda .

CELL, 2015, 161 (07) :1681-1696

[2] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[3] Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration [J].

Altman, Douglas G. ;

McShane, Lisa M. ;

Sauerbrei, Willi ;

Taube, Sheila E. .

PLOS MEDICINE, 2012, 9 (05)

[4] Final Version of 2009 AJCC Melanoma Staging and Classification [J].

Balch, Charles M. ;

Gershenwald, Jeffrey E. ;

Soong, Seng-jaw ;

Thompson, John F. ;

Atkins, Michael B. ;

Byrd, David R. ;

Buzaid, Antonio C. ;

Cochran, Alistair J. ;

Coit, Daniel G. ;

Ding, Shouluan ;

Eggermont, Alexander M. ;

Flaherty, Keith T. ;

Gimotty, Phyllis A. ;

Kirkwood, John M. ;

McMasters, Kelly M. ;

Mihm, Martin C., Jr. ;

Morton, Donald L. ;

Ross, Merrick I. ;

Sober, Arthur J. ;

Sondak, Vernon K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206

[5] Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients [J].

Cha, Edward ;

Klinger, Mark ;

Hou, Yafei ;

Cummings, Craig ;

Ribas, Antoni ;

Faham, Malek ;

Fong, Lawrence .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (238)

[6] Monitoring the immune competence of cancer patients to predict outcome [J].

Chang, Serena ;

Kohrt, Holbrook ;

Maecker, Holden T. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2014, 63 (07) :713-719

[7] Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo [J].

Das, Rituparna ;

Verma, Rakesh ;

Sznol, Mario ;

Boddupalli, Chandra Sekhar ;

Gettinger, Scott N. ;

Kluger, Harriet ;

Callahan, Margaret ;

Wolchok, Jedd D. ;

Halaban, Ruth ;

Dhodapkar, Madhav V. ;

Dhodapkar, Kavita M. .

JOURNAL OF IMMUNOLOGY, 2015, 194 (03) :950-959

[8] Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy [J].

Davoli, Teresa ;

Uno, Hajime ;

Wooten, Eric C. ;

Elledge, Stephen J. .

SCIENCE, 2017, 355 (6322)

[9] Unraveling cell populations in tumors by single-cell mass cytometry [J].

Di Palma, Serena ;

Bodenmiller, Bernd .

CURRENT OPINION IN BIOTECHNOLOGY, 2015, 31 :122-129

[10] Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma [J].

Diem, S. ;

Kasenda, B. ;

Spain, L. ;

Martin-Liberal, J. ;

Marconcini, R. ;

Gore, M. ;

Larkin, J. .

BRITISH JOURNAL OF CANCER, 2016, 114 (03) :256-261

← 1 2 3 4 5 6 7 →